摘要
Abstract
Objective To explore the effect of radionuclide strontium chloride combined with zoledronic acid in the treatment of breast cancer with bone metastasis.Methods Seventy patients with bone metastasis of breast cancer admitted to Zibo Hospital of Shandong Nursing and Health Group from February 2018 to February 2022 were selected as the study objects,and were divided into experimental group and control group according to different treatment methods,with 35 cases in each group.The control group was given zoledronic acid,and the experimental group was given radionuclide strontium chloride on the basis of the control group.The pain status,tumor markers,bone metabolism indexes and the occurrence of adverse reactions were compared between the two groups.Results After treatment and at the first follow-up,NRS scores,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),bone resorption index type I collagen carboxy-terminal peptide β special sequence(β-CTX)and total type I collagen amino terminal prolongating peptide(TPINP)were decreased by in both groups(P＜0.05).NRS score,CEA,CA125,β-CTX and TPINP levels in experimental groups were lower than those in control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the experimental group(28.57%)and the control group(20.00%)(P＞0.05).Conclusion Radionuclide strontium chloride combined with zoledronic acid can effectively relieve pain,reduce the level of tumor markers,delay cancer cell metastasis and improve the condition of breast cancer patients with bone metastasis.关键词
放射性核素氯化锶/唑来膦酸/乳腺癌骨转移/疗效Key words
Radionuclide strontium chloride/Zoledronic acid/Bone metastasis of breast cancer/Curative effect分类
医药卫生
